Last week, Novavax said it has applied for emergency use authorization (EUA) in India, the Philippines and Indonesia through its partner Serum Institute. Unless the main Novavax is granted approval, Serum Institute cannot receive approval in India according to its clinical trial protocol. Serum Institute did not answer an email asking how it filed for Covovax approval when Novavax was yet to be approved anywhere. In India, where the government is targeting to bring over one billion doses by the end of this year, the Novavax approval is critical. The Novavax vaccine uses a recombinant protein technology to generate an immune response against the SARS Cov2 virus.

Source: Mint August 08, 2021 18:22 UTC